Polatuzumab vedotin, CAS 1313206-42-6

Product Description: Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL)[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Liebers N, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul 13;5(13):2707-2716./[2]Li D, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019 Oct;176(19):3805-3818.

CAS Number: 1313206-42-6

Molecular Weight: 150000 (average)

Compound Purity: 98.87

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Antibody-Drug Conjugates (ADCs)

• Artikelnummer: MEXHY-132253-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-132253-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK